And by only, I mean the only one....period in existence at least according to orange book.

"The renouncements of the combined entity’s interest in the isradipine and loxapine succinate

agreements will similarly preserve competition in each of those markets."

"Isradipine capsules are used to treat high blood pressure and are the generic version of

Dynacirc.  Branded Dynacirc has been discontinued and Watson manufactures the only

generic product available today.  Actavis has a marketing and profit-sharing arrangement

with the best-positioned entrant, which is a likely potential supplier in the concentrated

market for isradipine capsules. "

It is a bit hard to read but the best positioned entrant is likely Mikah

http://www.accessdata.fda.gov/scripts/cder/ob...tempai.cfm